HR+/HER2- breast cancer is one of the most prevalent breast cancer subtypes, impacting a substantial number of patients worldwide. With continuous advancements in oncology, novel drug candidates are being developed, holding the potential to revolutionize HR+/HER2- breast cancer treatment. These innovations aim to enhance efficacy, improve patient outcomes, and drive significant shifts in...